.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,221,383

« Back to Dashboard

Details for Patent: 6,221,383

Title: Solubility parameter based drug delivery system and method for altering drug saturation concentration
Abstract:A blend of at least two polymers, or at least one polymer and a soluble polyvinylpyrrolidone, in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin. According to the invention, soluble polyvinylpyrrolidone can be used to prevent crystallization of the drug, without affecting the rate of drug delivery from the pressure-sensitive adhesive composition.
Inventor(s): Miranda; Jesus (Miami, FL), Sablotsky; Steven (Miami, FL)
Assignee: Noven Pharmaceuticals, Inc. (Miami, FL)
Filing Date:May 25, 1999
Application Number:09/318,121
Claims:1. A pressure-sensitive adhesive composition suitable for use in a transdermal drug delivery system, which composition comprises a blend of:

(a) a rubber adhesive, wherein the rubber adhesive is present in an amount from 5% to 97% by weight of the total composition;

(b) a polyacrylate in an amount from 1% to 85% by weight of the total composition, wherein the ratio of the polyacrylate to the rubber adhesive is from 2:98 to 96:4;

(c) a therapeutically effective amount a mixture of two or more drugs for transdermal drug delivery, wherein the drug is present in an amount weight 0.1% to 50% by weight of the total composition, and wherein said two or more drugs include an androgenic steroid and an estrogen; and

(d) a soluble polyvinylpyrrolidone, wherein the soluble polyvinylpyrrolidone is present in an amount of 1% to 20% by weight of the total composition,

wherein the ratio of the drug to the soluble polyvinylpyrrolidone is from 1:10 to 10:1, and

wherein the amount of soluble polyvinylpyrrolidone is sufficient to solubilize all of the drug which is present in an amount that would exceed its solubility in a composition that contains a rubber adhesive and a polyacrylate, but lacks soluble polyvinylpyrrolidone.

2. A pressure-sensitive adhesive composition suitable for use in a transdermal drug delivery system, which composition comprises a blend of:

(a) a synthetic elastomeric polymer;

(b) a soluble polyvinylpyrrolidone;

(c) a therapeutically effective amount of a drug or a mixture of two or more drugs for transdermal drug delivery, wherein said two or more drugs include an androgenic steroid and an estrogen; and

(d) optionally one or more additives selected from the group consisting of enhancers, fillers, plasticizers, tackifying agents, and co-solvents.

3. A pressure-sensitive adhesive composition suitable for use in a transdermal drug delivery system, which composition comprises a blend of

(a) a rubber;

(b) a soluble polyvinylpyrrolidone;

(c) a therapeutically effective amount of a drug or a mixture of two or more drugs for transdermal drug delivery, wherein said two or more drugs include an androgenic steroid and an estrogen; and

(d) optionally one or more additives selected from the group consisting of enhancers, fillers, plasticizers, tackifying agents, and co-solvents.

4. A pressure-sensitive adhesive composition suitable for use in a transdermal drug delivery system, which composition comprises a blend of:

(a) a rubber adhesive, wherein the rubber adhesive is present in an amount from 5% to 97% by weight of the total composition;

(b) a polyacrylate in an amount from 1% to 85% by weight of the total composition, wherein the ratio of the polyacrylate to the rubber adhesive is from 2:98 to 96:4;

(c) a therapeutically effective amount a drug for transdermal drug delivery, wherein the drug is present in an amount of 0.1% to 50% by weight of the total composition, and wherein said drug is selected from the group consisting of terbinafine, sumatriptan, physostigmine, loratadine, simvastatin, pravstatin, methimazole, alendranate, etidronate, ropinirole, pramipexole, fenoldopam, and nimesulide; and

(d) a soluble polyvinylpyrrolidone, wherein the soluble polyvinylpyrrolidone is present in an amount of 1% to 20% by weight of the total composition,

wherein the ratio of the drug to the soluble polyvinylpyrrolidone is from 1:10 to 10:1, and

wherein the amount of soluble polyvinylpyrrolidone is sufficient to solubilize all of the drug which is present in an amount that would exceed its solubility in a composition that contains a rubber adhesive and a polyacrylate, but lacks soluble polyvinylpyrrolidone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc